Welcome to our dedicated page for Xtant Medical Holdings news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical Holdings stock.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is a leader in the field of regenerative medicine and surgical solutions for spinal disorders. The company designs, develops, and markets a comprehensive range of orthobiologics and spinal implant systems to aid spinal fusion in complex spine, deformity, and degenerative procedures. Their offerings are widely utilized by orthopedic spine surgeons and neurosurgeons for treating various spinal disorders across cervical, thoracolumbar, and interbody regions.
Xtant Medical's product portfolio includes notable biomaterial products such as OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the 3Demin line. These products are essential for promoting bone healing, and their applications extend to orthopedic disorders and cranial, foot, and ankle surgeries. The company's innovative solutions are distributed in both domestic and international markets, making a significant impact on global neurological and orthopedic surgery markets.
In recent developments, Xtant Medical has successfully raised its 2023 annual revenue guidance to $88 million - $91 million. Furthermore, the company has projected its full-year 2024 revenue guidance between $112 million - $116 million, signifying strong growth and operational efficiency. The financial results for the first quarter of 2024 were impressive, with total revenue reaching $27.9 million, an increase of 55% compared to the previous year. This growth was driven by strategic acquisitions, increased independent agent sales, and additional product sales.
Xtant Medical is dedicated to honoring the gift of donation, enabling patients to live full and complete lives. The team at Xtant is composed of dedicated and talented individuals who operate with the highest integrity to serve their customers. The company's mission and values are reflected in their continuous innovation and commitment to providing high-quality medical solutions.
Xtant Medical Holdings (NYSE American: XTNT) will announce its Q1 2023 financial results on May 4, 2023, before market open. A conference call will follow at 9:00 AM ET, led by CEO Sean Browne and CFO Scott Neils, to discuss the results. Interested parties can join through dial-in numbers or via a webcast registration link provided in the release. Xtant Medical specializes in medical technology, focusing on orthobiologics and spinal implant systems for spinal fusion procedures. The company emphasizes integrity and dedication in serving its customers. For further information, a replay of the call will be accessible on the company's website after the live event.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported strong fourth quarter and full year 2022 financial results, with revenues growing 9% to $15.3 million for Q4 and 5% to $58.0 million for the full year. The company's biologics products drove a 14% revenue increase in Q4. Despite a decline in gross margin to 54.4% due to higher production costs, the acquisition of the Coflex® product line enhances its offerings. The net loss for 2022 increased to $8.5 million, or $0.09 per share, signaling challenges despite revenue growth. A conference call is scheduled to discuss these results further.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is set to release its financial results for the fourth quarter and full year ended December 31, 2022, before the market opens on March 7, 2023. The results will be discussed in a conference call hosted by CEO Sean Browne and CFO Scott Neils at 9:00 AM ET on the same day. Investors can participate by calling 877-407-6184 or registering for the webcast on the company’s website. Xtant specializes in surgical solutions for spinal disorders, focusing on orthobiologics and spinal implant systems designed to facilitate spinal fusion.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has acquired the Coflex® and Cofix product lines from Surgalign Holdings, Inc. for $17 million. The Coflex device is the only FDA PMA-approved implant for treating lumbar spinal stenosis (LSS) and is used globally. With approximately 2.4 million LSS patients, this acquisition is significant for Xtant, which anticipates adding $14 million in annual revenue. This move aims to enhance Xtant's market position by expanding its product offerings and distributor network, supporting its growth strategy in the outpatient procedure segment.
Xtant Medical Holdings, a global medical technology company, announced that CEO Sean Browne will present at the Canaccord Musculoskeletal Conference on March 7, 2023, at 3:30 p.m. PT in Las Vegas. The event will be accessible via a live webcast on the company’s website.
A replay of the webcast will be available for approximately 90 days post-presentation. Xtant Medical focuses on surgical solutions for spinal disorders, designing and developing orthobiologics and spinal implant systems for complex spinal procedures.
Xtant Medical Holdings, Inc. (XTNT) announced the appointment of Mark Schallenberger as Chief Operations Officer, effective January 16, 2023. Schallenberger, who has over 12 years of experience in orthobiologics, will focus on modernizing production, optimizing operations, and diversifying product lines. President Sean Browne expressed enthusiasm about Schallenberger's role in driving growth. Xtant Medical specializes in surgical solutions for spinal disorders, emphasizing innovation in orthobiologics and spinal implants.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported a 5% increase in third quarter 2022 revenues, reaching $14.5 million, up from $13.8 million in Q3 2021. This growth was driven by a 12% rise in the biologics segment, attributed to the launch of OsteoFactor™ and OsteoVive® Plus products. Gross margin improved to 54.6%, while operating expenses rose to $9.8 million, resulting in a net loss of $2.4 million or $0.03 per share. The company expects to reach full operating capacity by Q1 2023, supported by a recent $9.75 million private placement.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its third-quarter financial results for the period ending September 30, 2022, on November 3, 2022, before market opening. A conference call led by CEO Sean Browne and CFO Scott Neils will follow at 9:00 AM ET to discuss these results. Investors are encouraged to participate via dial-in or web registration, with a replay available thereafter on the company's website.
Xtant Medical focuses on innovative surgical solutions for spinal disorders.
FAQ
What is the current stock price of Xtant Medical Holdings (XTNT)?
What is the market cap of Xtant Medical Holdings (XTNT)?
What does Xtant Medical Holdings, Inc. specialize in?
Which products are part of Xtant Medical's portfolio?
What are the recent financial achievements of Xtant Medical?
Who are the primary users of Xtant Medical's products?
What recent business highlights has Xtant Medical reported?
Where can I find more information about Xtant Medical?
How does Xtant Medical contribute to patient care?
What are Xtant Medical's core competencies?
How can I contact Xtant Medical for investor relations?
What is the mission of Xtant Medical?
